IHC News and Research

RSS
Support for enteric nervous system pathology in prodromal PD

Support for enteric nervous system pathology in prodromal PD

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics announces launch of new germline cancer predisposition testing services

Automated droplet-based surface sampling probe analyzes liver biopsy sample in 10 minutes

Automated droplet-based surface sampling probe analyzes liver biopsy sample in 10 minutes

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

VENTANA ALK (D5F3) CDx Assay receives FDA approval

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Researchers report new label-free chemical imaging that provides similar information as molecular stains

Researchers report new label-free chemical imaging that provides similar information as molecular stains

Flagship Biosciences customizes assay development and tissue image analysis for advanced cell diagnostics RNAscope platform

Flagship Biosciences customizes assay development and tissue image analysis for advanced cell diagnostics RNAscope platform